Robert M. Davis - 05 May 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 May 2026, 11:52:37 UTC
Prior SEC filing
01 May 2026
Next SEC filing
11 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis

Key filing fact

Robert M. Davis filed Form 4 for Merck & Co., Inc. (MRK) on 07 May 2026.

Key facts

  • This page summarizes Robert M. Davis's Form 4 filing for Merck & Co., Inc. (MRK).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 07 May 2026, 11:52.

Change

  • Previous filing in this sequence was filed on 01 May 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001363076 Primary reporting owner

Davis Robert M

Relationship
Chairman, CEO & President, Director
Address
MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Robert M. Davis
Signature date
07 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
450,351
Date
05 May 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRK transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares
+47,724
Change %
Price
$0.000000*
Shares after
47,724
Date
05 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
47,724
Exercise price
Footnotes
F1, F2
MRK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+139,697
Change %
Price
$0.000000*
Shares after
139,697
Date
05 May 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
139,697
Exercise price
$113.15
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

Footnote F2

These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.

Footnote F3

The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .